Menu Close

Segment Wealth Management LLC Acquires 4,083 Shares of Johnson & Johnson (NYSE:JNJ)

view original post

Segment Wealth Management LLC grew its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 6.9% in the first quarter, HoldingsChannel reports. The fund owned 62,897 shares of the company’s stock after buying an additional 4,083 shares during the period. Johnson & Johnson accounts for 1.1% of Segment Wealth Management LLC’s portfolio, making the stock its 20th largest position. Segment Wealth Management LLC’s holdings in Johnson & Johnson were worth $11,147,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Family CFO Inc bought a new stake in Johnson & Johnson during the fourth quarter worth about $26,000. Steward Financial Group LLC bought a new stake in Johnson & Johnson during the fourth quarter worth about $34,000. Joseph P. Lucia & Associates LLC bought a new stake in Johnson & Johnson during the first quarter worth about $38,000. Advocacy Wealth Management Services LLC lifted its position in Johnson & Johnson by 41.4% during the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after purchasing an additional 67 shares during the period. Finally, Iron Horse Wealth Management LLC lifted its position in Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares during the period. 68.78% of the stock is owned by institutional investors.

Several equities research analysts recently weighed in on JNJ shares. Daiwa Capital Markets started coverage on shares of Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating for the company. Citigroup cut their price objective on shares of Johnson & Johnson from $210.00 to $205.00 in a research report on Tuesday, May 17th. Sanford C. Bernstein downgraded Johnson & Johnson from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $180.00 to $183.00 in a research note on Wednesday, March 16th. Raymond James boosted their target price on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, Morgan Stanley boosted their target price on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $190.67.

Johnson & Johnson stock opened at $175.85 on Wednesday. The business has a 50 day moving average of $176.84 and a 200-day moving average of $174.22. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The company has a market capitalization of $462.73 billion, a P/E ratio of 23.70, a P/E/G ratio of 3.53 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJGet Rating) last released its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company had revenue of $23.43 billion during the quarter, compared to the consensus estimate of $23.62 billion. During the same quarter in the prior year, the firm posted $2.59 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.23 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a $1.13 dividend. The ex-dividend date of this dividend was Monday, May 23rd. This represents a $4.52 annualized dividend and a dividend yield of 2.57%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio is currently 60.92%.

In other Johnson & Johnson news, insider William Hait sold 29,699 shares of the stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the completion of the sale, the insider now owns 80,236 shares of the company’s stock, valued at approximately $14,729,724.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. Insiders sold 78,161 shares of company stock valued at $13,895,302 in the last ninety days. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.